Clinical trial · Observational
Reporting, Evaluating, Preventing and Treating the Cardiotoxicity Induced by Anticancer Drugs During a Specific Cardio-oncology Consult and Follow up in Routine Care
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 12, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260912-000001
Summary
Brief summary (as posted)
Several Drugs used in routine care in oncology induce rare but often severe or fatal cardiovascular or metabolic side effects. This study will investigate, evaluate, report and treat the cardiovascular side effects of anticancer drugs, through a specific cardiovascular routine checkup and follow-up taking place in several Cardio-oncology programs throughout France. The different including centers will be: Assistance Publique - Hôpitaux de Paris (APHP.6: Pitié-Salpétrière, Saint Antoine and Tenon's hospitals, Paris, France).
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cardiac Complication | — | UNRESOLVED | — |
| Cardiac Disorder | — | UNRESOLVED | — |
| Cardiac Insufficiency | — | UNRESOLVED | — |
| Cardiovascular Complication | — | UNRESOLVED | — |
| Cardiovascular Insufficiency | — | UNRESOLVED | — |
| Metabolic Disorder | — | UNRESOLVED | — |
| Oncologic Complications | — | UNRESOLVED | — |
| Vascular Disorder | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Anti-Cancer Agents | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Number of patients having a benefit after this specific cardio-oncology check up and follow up
- timeFrame
- 5 years
Secondary outcomes (14)
- measure
- Evaluating the overall survival of patients suffering from cardiovascular or metabolic side effect of oncology treatments
- timeFrame
- 5 years
- measure
- All relevants staisticals associations between adverse events and anticancer drugs
- timeFrame
- 5 years
- measure
- All relevant statistical associations between cardiovascular toxicities, and anticancer drugs
- timeFrame
- 5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Suffering a cancer * Evaluated within a cardio-oncology program Exclusion Criteria: * None
References
Publications (2)
- BACKGROUNDSalem JE, Allenbach Y, Vozy A, Brechot N, Johnson DB, Moslehi JJ, Kerneis M. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis. N Engl J Med. 2019 Jun 13;380(24):2377-2379. doi: 10.1056/NEJMc1901677. No abstract available. PMID 31189043
- DERIVEDDolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, Sassier M, Plane AF, Comoz F, Cohen AA, Thuny FR, Cautela J, Alexandre J. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020 Jan;8(1):e000261. doi: 10.1136/jitc-2019-000261. PMID 31988143